methyl α-methyl-5-chloro-2-nitrobenzeneacetate | 86790-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl α-methyl-5-chloro-2-nitrobenzeneacetate
• 英文别名: methyl 2-methyl-2-(2-nitro-5-chlorophenyl)acetate；methyl 2-(2-nitro-5-chlorobenzene)propionate；methyl 2-(5-chloro-2-nitrophenyl)propanoate
• CAS: 86790-37-6
• 化学式: C₁₀H₁₀ClNO₄
• 分子量: 243.647
• InChiKey: UEKWQUOVODAXNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl α-methyl-5-chloro-2-nitrobenzeneacetate 在 铁粉 水 、 乙酸乙酯 、 氯化钠 、 magnesium sulfate 、 正己烷 、 异丙醚 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以to obtain the title compound (7.12 g, 84%) as a pale brown solid的产率得到5-氯-1,3-二氢-3-甲基-2H-吲哚-2-酮
  参考文献：
  名称：

  IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE

  摘要：

  提供了一种咪唑衍生物，可用作治疗血栓的药物，其化学式表示为（I）：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价线性烃基，X代表可选取代的二价烃基，Y代表-CO-，-S（O）-，-S（O）2-或键，环A代表可选取代的吡咯烷环，可选取代的哌啶环或可选取代的过氢化脂肪环，Z1和Z3独立地代表键或可选取代的二价线性烃基，Z2代表-N（R1）-，-O-，-S（O）-，-S（O）2-，-CO-，-CH（R1）-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所代表的取代基可以与R1一起形成可选取代的环，a代表0，1或2。

  公开号：

  US20110009389A1
• 作为产物：
  描述：

  methyl 2-(2-bromo-3-chloro-6-nitrophenyl)propanoate 生成 methyl α-methyl-5-chloro-2-nitrobenzeneacetate
  参考文献：
  名称：

  RAJANBABU, THALIYIL V.

  摘要：

  DOI：

文献信息

• Nucleophilic addition of silyl enol ethers to aromatic nitro compounds: scope and mechanism of reaction
  作者：T. V. RajanBabu、G. S. Reddy、Tadamichi Fukunaga

  DOI：10.1021/ja00305a024

  日期：1985.9

  chloride are not displaced in the reaction, suggesting the absence of radical ion intermediates. Dihydroaromatic nitro derivatives can be isolated in some cases, such as anthracene and naphthalene systems which are less prone to rearomatize. The use of silicon reagents in organic synthesis has been ex- panding rapidly in the past few year^,^-^ and versatile methods for carbon-carbon bond formations have been

  与碱金属烯醇化物形成鲜明对比的是，在氟离子源的存在下，甲硅烷基烯醇醚和烯酮甲硅烷基缩醛加成到芳香硝基化合物中，得到中间体二氢芳香硝基化合物，这可以通过 NMR 观察到。中间体与硼胺或 DDQ 的原位氧化以中等至高产率产生α-硝基芳基羰基化合物。该反应适用于烷基、烷氧基和卤素取代的硝基苯以及杂环和稠合硝基芳族化合物。虽然硝基的邻位取代主要用空间上要求不高的甲硅烷基试剂，但对位取代产物仅用体积大的试剂获得。然而，通过用适当的基团（例如氯）封闭对位，可以将加成指向邻位。卤代硝基芳烃和对硝基枯烯基氯的卤素原子在反应中没有被置换，表明不存在自由基离子中间体。在某些情况下可以分离二氢芳族硝基衍生物，例如不太容易重构化的蒽和萘系统。在过去的几年里，硅试剂在有机合成中的应用迅速扩大，基于由氟离子源活化的甲硅烷基烯醇醚，已经开发出用于碳-碳键形成的通用方法。各种研究小组已经报道了烷基化^、^^^^ 芳基化~ns、~aldol
• Nucleophilic substitution process combined with additional reaction steps
  申请人：Ethyl Corporation

  公开号：US04581463A1

  公开（公告）日：1986-04-08

  Halonitroarylacetic acid esters are prepared by reacting a halonitroaromatic compound with an alpha,alpha-disubstituted acetic acid ester in an inert solvent and in the presence of a base. The halonitroarylacetic acid esters formed by the process can be readily converted into derivatives, such as pharmaceuticals.

  Halonitroarylacetic酸酯是通过在惰性溶剂中，在碱的存在下将halonitroaromatic化合物与alpha，alpha-二取代醋酸酯反应而制备的。通过该过程形成的halonitroarylacetic酸酯可以轻松地转化为药物等衍生物。
• Imidazole derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070004736A1

  公开（公告）日：2007-01-04

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，用作治疗血栓的药物，其化学式表示为(I)式：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价直链烃基，X代表可选取代的二价烃基，Y代表-CO-、-S(O)-、-S(O)2-或键，环A代表可选取代的吡咯烷环、可选取代的哌啶环或可选取代的过氢杂环己烷环，Z1和Z3独立地代表键或可选取代的二价直链烃基，Z2代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所具有的取代基可以与R1一起形成可选取代的环，a代表0、1或2。
• IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE
  申请人：KUBO Keiji

  公开号：US20110009389A1

  公开（公告）日：2011-01-13

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，可用作治疗血栓的药物，其化学式表示为（I）：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价线性烃基，X代表可选取代的二价烃基，Y代表-CO-，-S（O）-，-S（O）2-或键，环A代表可选取代的吡咯烷环，可选取代的哌啶环或可选取代的过氢化脂肪环，Z1和Z3独立地代表键或可选取代的二价线性烃基，Z2代表-N（R1）-，-O-，-S（O）-，-S（O）2-，-CO-，-CH（R1）-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所代表的取代基可以与R1一起形成可选取代的环，a代表0，1或2。
• IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1564213A1

  公开（公告）日：2005-08-17

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)2- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z1 and Z3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z2 represents -N(R1)-, -O-, - S(O)-, -S(O)2-, -CO-, -CH(R1)- or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，可用作血栓治疗剂，其由式(I)表示： 其中 R 代表任选取代的环状烃基或任选取代的杂环基，W 代表键或任选取代的二价线性烃基，X 代表任选取代的二价烃基，Y 代表 -CO-、-S(O)-、-S(O)2- 或键，环 A 代表任选取代的吡咯烷环、任选取代的哌啶环或任选取代的全氢氮杂卓环、Z1 和 Z3 独立地代表键或任选取代的二价线性烃基，Z2 代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)- 或键，环 B 代表任选取代的咪唑环，其中环 B 所代表的任选取代的咪唑环可能具有的取代基可与 R1 一起形成任选取代的环，a 代表 0、1 或 2。